.svg "CancerLinQ Logo Update 2025 (RGB)"){kind=small}
Manuscripts
February 22, 2023
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
PharmacoEconomics - Open
Verhoek A et al
January 10, 2023
Case studies for overcoming challenges in using big data in cancer
Cancer Research
Sweeney SM et al
January 10, 2023
Challenges to using big data in cancer
Cancer Research
Sweeney SM et al
August 10, 2022
Incidence of SARS-CoV-2 and subsequent mortality in a multi-site cohort of patients with cancer in the CancerLinQ Discovery database
JCO Oncology Practice
Ray E et al
June 3, 2022
Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data
Drugs - Real World Outcomes
Nieva J et al
May 1, 2022
Reaching beyond maximum grade: Progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology
Thanarajasingam G et al
April 28, 2022
Cancer registry data linkage of electronic health record data from ASCO's CancerLinQ: Evaluation of advantages, limitations, and lessons learned
JCO Clinical Cancer Informatics
Charlton M et al
February 22, 2022
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ study
Breast Cancer Research and Treatment
Miller RS et al
January 7, 2022
Quantitating and assessing interoperability between electronic health records
Journal of the American Medical Informatics Association
Bernstam E et al
Abstracts
June 2, 2023
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations
ASCO Annual Meeting 2023
Gray J E et al
June 2, 2023
Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery Multiple Myeloma dataset
ASCO Annual Meeting 2023
Shou K J et al
June 2, 2023
Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver
ASCO Annual Meeting 2023
Ryder A et al
June 2, 2023
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification
ASCO Annual Meeting 2023
Ryder A et al
June 2, 2023
Assessment of electronic health record (EHR)-based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non-small-cell lung cancer (eNSCLC)
ASCO Annual Meeting 2023
Honarvar H et al
June 2, 2023
Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC)
ASCO Annual Meeting 2023
Pisano S et al
June 2, 2023
Identification of biomarkers for early progression in muscle invasive bladder cancer (MIBC) using real-world data
ASCO Annual Meeting 2023
Singh N et al
June 2, 2023
Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence
ASCO Annual Meeting 2023
Mueller J et al
June 2, 2023
Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale
ASCO Annual Meeting 2023
Agrawal S et al
.svg "CancerLinQ Logo (White Cancer)"){kind=small}